Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

ADDvise Group, Audiocast, Q3'25

By Inderes10/23/2025, 12:00 PM
ADDvise Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Staffan Torstensson
00:00 - 18:50

Thank you, operator, and good afternoon to all of you. Our performance in the third quarter clearly reflects the impact of our ongoing efficiency initiatives, including the improved capital structure finalized during the first half of this year. Cash flow and earnings were in line with our expectations. The top line growth was somewhat soft in the quarter, mainly due to a single large order of lab equipment for Eli Lilly worth 23 million, which was invoiced in Q3 2024. Despite that, we saw strong momentum in our healthcare, consumables, and clinical trials business. We continue to see healthy demand for medical equipment across Europe as well as in North and South America. From a global perspective, 2025 has been turbulent so far, with friction in world trade and ongoing geopolitical tensions. We are closely monitoring these developments but choose to focus on things we can influence, and that is why we continue to work hard every day to create value for our customers and shareholders as efficiently as possible. We are also experiencing headwinds from the strengthening of the Swedish krona, which has impacted both our top line and earnings through translation effects. Looking ahead, our focus remains clear, strong, and growing. Cash flow generated by our existing group companies enables us to acquire additional cash flow and drive long-term shareholder value. With that, let's take a closer look at our Q3 results. Our net sales came in at 363 million SEK, which took us to a year-over-year decline of 4.8%. Adjusted for FX and excluding certain factors, our order intake in the quarter declined by 17%, or 12% when FX adjusted, mainly due to the large order from Saab in Q3 2024, which was 32.5 million. The year-to-date figure is also impacted by the larger Clean Rooms orders we received last year. Within the lab segment. Order intake for the quarter showed healthy growth of roughly 14%, but the year-to-date figures were heavily affected by last year's record Clean Rooms orders. Orders are the largest ever within the business area. We will continue to see some volatility in order intake, given the project nature of these larger orders. However, excluding the impact of Eli Lilly and the clean room orders. Our year-to-date order intake showed slight growth. It is also important to note that order intake is not a relevant leading indicator for most of our businesses, since we deliver continuously against orders rather than building backlog. EBITA came in at 56 million SEK, in line with last year. This takes us to a margin of 16%, stronger than Q3 last year, where we reached roughly 14%. Looking at the cash flow from operations, it came in strong at 35 million SEK. A big contributor was lower financing expenses. 21 million versus 44 for Q3 last year. Net leverage for the end of the period was 3.2 times, an increase from three times last quarter, mainly affected by paid earnouts. Adjusted net profit came in at 19 million, compared to minus five in Q3 last year. Again, lower financial costs, lower tax, and increased operational efficiency were the drivers. These were the drivers. Coming into the commercial and operational highlights of this quarter, we saw balanced business momentum in both healthcare and lab. During the quarter, we continued to focus on efficiency initiatives to ensure that we are maximizing our potential to drive value. EBITDA and EBITDA margin improved year over year, as the margin came in at 15.5% compared to 13.7%, driven mainly by product mix and efficiency improvements. Managing working capital is one of our top priorities. During the quarter, we saw a healthy increase in cash flow compared to the same quarter last year. As mentioned before, lower financial expenses, lower tax payments, and moderate working capital build, which came in at 5.5 million SEK. The main drivers in terms of geography were approximately half, or 47%, of our sales in the quarter coming from the US or North America. And our second largest market is Europe, and the third is South America. Looking at our sales by product category, the top three for the quarter are Laboratory Equipment at 36%, Medical Consumables at 37%, and Medical Equipment at 22%. High activity in medical equipment and continued balanced demand in clinical trials. Lab equipment is, as mentioned earlier, affected by tough comparables due to the sale of 2.5 to 2.1 million EUR to Eli Lilly in Q3 last year. Splitting the group into healthcare and lab, and looking at healthcare, our sales came in at 234 million SEK in the quarter. Organic growth was close to flat. It was 0.2% FX adjusted and -6.2% non-adjusted. Looking at the year-to-date figure, we saw an organic decrease of -1.4%. Adjusted for FX, there is a growth of 4.2%. The lab segment reported sales of 129 million SEK for the quarter. Organic sales came in at -16.2%, FX adjusted. We ended up at -12.7%. Looking at profit margins, healthcare came in at a 16% EBITDA margin and lab at 17.2% in the quarter. Isolated. Looking at net sales by geography for the healthcare segment. North America continues to be a key market with approximately 60% of sales, and it is expected to remain so for a long time. Europe has shown good development in the lab segment. Europe is the largest market followed by the US. We remain focused on profitable growth, stable returns and maintaining well-balanced debt levels. We remain focused on profitable growth, stable returns, and maintaining well-balanced debt levels. A strong emphasis is placed on EBITDA growth and return on capital employed as our key financial performance indicators. Long-term EBITDA growth will be driven by a combination of organic expansion and strategic acquisitions. Our long-term target is to double EBITA every five years. We are committed to maintaining a maximum net debt to EBITDA ratio of three times. While a dividend remains part of our long-term financial framework. Distributions will be considered only once all other long-term financial targets are met at a sustainable and appropriate level. I'm now handing over to Johan to take you through the group's financial performance. We are committed to maintaining a maximum net debt to EBITDA ratio of three times. Thank you, Staffan, and good afternoon, everyone. I'm happy to be here today and take you through the figures for the third quarter of 2025. EBITDA, which is ADDvise Group's main metric for measuring profit, gives a fair view of the financial performance of our companies. EBITDA is defined as operating profit before amortization, impairment expenses, and revaluations related to acquisitions, as well as non-recurring items. And just as a reminder, EBITDA is our key metric from this year, 2025, and figures in this graph have been historically adjusted with the new definition. And EBITDA in the third quarter amounted to 56 million, which corresponds to a margin of 15.5%. EBITDA has improved by 1 million compared to the same period last year, and the EBITDA margin has improved to 15.5% compared to 13.7% last year. And I'm happy to see that profit is increasing despite currency headwinds from both US dollars and Brazilian reais. This is thanks to all of our companies working hard every day to improve operational efficiency with a focus on profit, profitability, and cash flow, which is the key to our long-term performance. As we have pointed out in earlier reports, 2024 faced tough comparables from 2023. The individual quarters of 2024 should be considered at a normal level of profits, which means that from Q4 2024 onwards, we see normalized levels of sales and profitability. Profitability on a rolling 12-month basis, and for the last 12 months, EBITDA amounts to 268 million, which corresponds to a margin of 16.5%. Moving on to cash flow and capital efficiency. And here, when we talk about cash generation, we look at the underlying cash flow generated by our businesses, with deductions from changes in working capital as well as depreciation and investments in our asset base, including lease payments. In the third quarter, we see a moderate working capital build of 5.5 million, mainly driven by an increase in accounts receivable. Working capital efficiency and optimization is and will always be a key focus area for us and our companies. Depreciation includes depreciation on fixed assets as well as on right-of-use assets related to leases, and the net between depreciation, leases, and investments is 2.3 million, indicating lower new investments compared to depreciation on existing assets, mainly driven by lower investments this year in production efficiency in South America, as well as the clinical trial business compared to last year. Total cash generation from operations in the quarter was 53 million, relative to an EBITDA of 56 million. We consider this a solid and satisfactory level of cash generation in the quarter, and a testament to our never-ending focus on cash flow return on capital employed, which measures profitability and how efficiently we use our capital. Our capital was 12% in the quarter, and this is one of our long-term financial targets with a long-term goal of 15% return on capital employed. Moving on to the financial position here, our long-term target is three times net debt over EBITDA. And net leverage at the end of Q3 was 3.2 times EBITDA. The new capital structure means significantly lower financing costs, which improves operating cash flow and reduces net leverage over time. Total financing expenses in Q3 were 21 million SEK compared to 44 million last year. In this quarter, this effect was offset by Earnout transactions, and the rights issue for the first half of this year added 457 million before transaction costs to the company. It also included warrants that could potentially add up to 114 million SEK to the company, or up to a maximum of 172 million in Q1 2026 if all warrants are fully exercised. Available liquidity is good. Cash at the end of the quarter was 131 million SEK. SEK, with an additional 114 million available in unused credit facilities. And that's all from me. I will now hand over to Staffan for some closing remarks. Thank you, Johan. I will summarize and give you our takeaways from this quarter before we open up for questions. We delivered solid cash generation in the third quarter. Organic sales declined by 4.8%. FX adjusted mainly due to the larger Eli Lilly order in Q3 2024, but EBITA still improved despite FX headwinds supported by operational efficiency and a stronger product mix. This was also the first quarter with the full effect of our improved capital structure, resulting in roughly 50% lower financial expenses. On the M&A side, we continue to evaluate interesting opportunities, including bolt-on acquisitions. There is no rush. It has to be right. With a solid foundation and a clear strategy focused on efficiency, financial discipline, and growth through organic means and acquisitions, we are well-positioned to deliver sustainable value for our clients and shareholders. Thank you for joining today. We open up for questions.

Operator
18:51 - 19:01

If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad.

Unknown 1
19:36 - 20:07

Hello. Peter. Maybe I could ask you a question on. You haven't seen any releases or you haven't actually sent out any releases on any large orders. Can you maybe talk a bit about if you have seen any changes in the market, or are you still out there trying to compete for those larger ones? It also included warrants that could potentially add up to 114 million SEK to the company, or up to a maximum of 172 million in Q1 2026 if all warrants are fully exercised.

Staffan Torstensson
20:10 - 21:06

Thank you. Peter. No. I guess we will continue to take larger orders, but it is extremely important that it should be on good terms for us. But there is no strategy shift in which we say no thanks or that we are not pursuing these typical opportunities. Larger orders are how we define them. So I guess from my perspective, I will continue to see. But of course, as you have reflected, we haven't closed any such orders in the last quarters. But hopefully, we will release some in the coming quarters.

Unknown 1
21:10 - 21:14

Do you have an estimated value for when you plan to release orders?

Staffan Torstensson
21:14 - 21:19

I guess we will continue to take larger orders, but it is extremely important that they should be on good terms for us. About €1 million. We release.

Unknown 1
21:21 - 21:53

I guess we will continue to take larger orders, but it is extremely important that it should be on good terms for us. I guess we will continue to take larger orders, but it is extremely important that it should be on good terms for us. Could I maybe also ask a few questions regarding the earnouts, the lion's share of them? Is he going to be paid off now in Q4 or Q1, and then maybe, in your bond prospectus, it's mentioned that you are also not in agreement on part of the earnout. Can you possibly elaborate on what has occurred?

Staffan Torstensson
21:55 - 22:48

No, I guess when it comes to cleaning and the earnout, there is a legal process ongoing. The dispute is clear that we think the calculation should be in one way and the counterparties in another. So, that process will have its own workflow. So, I can't comment more in detail on that one. However, as it's correct that we have our latest acquisitions. We have earnouts. That will be based on 2025, meaning that we will hopefully pay them in full during the beginning of next year.

Unknown 1
22:52 - 23:14

I guess we will continue to take larger orders, but it is extremely important that it should be on good terms for us. I guess we will continue to take larger orders, but it is extremely important that it should be on good terms for us. Maybe just a final question. The cost reductions you have implemented during the last quarters. Is it all impacting the Q3 numbers or is there anything more to come?

Staffan Torstensson
23:19 - 23:34

Uh, most of it is affecting Q3. But it's a continuing process. I mean, we are very focused on ensuring that all costs we have should bring value.

Unknown 1
23:39 - 23:40

Great. Thank you. Staffan Torstensson.

Staffan Torstensson
23:41 - 23:42

Thank you.

Operator
23:48 - 24:04

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Filip Ekengren from ABG Sundal Collier. Please go ahead.

Unknown 2
24:05 - 24:21

Good afternoon, everyone. Sorry if I missed this earlier, but could you please clarify? But could you just remind me, do we have any kind of comparables in Q4 last year that we should keep in mind when setting numbers for Q4 this year? Is there anything we should keep in mind? Thank you.

Staffan Torstensson
24:23 - 24:43

And not when it comes to larger orders. Of course. The Q4 quarter last year was strong, and seasonally, Q4 is typically a strong quarter, so we're expecting a strong quarter for this year as well.

Unknown 2
24:45 - 25:07

Perfect. Sounds good. And, kind of. With that in mind, how should we think about margins going into Q4? I appreciate that you don't want to provide specific guidance on that, but can you discuss what you're observing in the market and how the businesses are performing? What are you seeing in terms of your cost reduction programs and other related factors? Thank you.

Staffan Torstensson
25:10 - 25:50

I think the important thing for me is the trend. Uh, that's one thing. So we always push for higher margins. However, it's extremely tough to give you clear guidance on that one. So. So, I mean, the trend is there, and commenting on healthcare versus lab in this quarter, it's clear that healthcare was performing well. And, lab was a bit on the soft side, even though it's generally based on the comparables there. So.

Unknown 2
25:53 - 25:55

Sounds good. I think that's all for me. Thank you.

Staffan Torstensson
25:56 - 25:56

Thank you.

Operator
26:05 - 26:11

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Staffan Torstensson
26:13 - 26:25

Thank you all. Have a good afternoon and talk to you next quarter. Thank you. Bye-bye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…